NASDAQ · IRON
Disc Medicine, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for IRON: Nov 5, 2026
Disc Medicine, Inc. Common Stock is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 6 analysts' forecasts, the consensus EPS forecast for the quarter is $-1.65. The reported EPS for the same quarter last year was $-1.77.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-1.65 | $-1.57 | $-1.76 | 6 |
| Dec 2026 | $-1.70 | $-1.60 | $-1.79 | 6 |
| Mar 2027 | $-1.74 | $-1.68 | $-1.83 | 3 |
| Jun 2027 | $-1.74 | $-1.56 | $-1.85 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Fintel · Barchart · MarketBeat- RTTNews · Oct 23, 10:53 AM EDTWeekly Buzz: AZN, ALVO Score FDA Nod; EYPT Cuts Jobs; RHHBY, GEHC Enter Deal; VERA Posts Trial Win(RTTNews) – Healthcare and biotech news this week centred on regulatory approvals, strategic deals, and pivotal clinical data.
- Fintel · Oct 23, 2:34 AM EDTDisc Medicine Consensus Price Target Increased by 12.67% to $118.56The average one-year price target for Disc Medicine (NASDAQGM:IRON) has been revised to $118.56 / share. This is an increase of 12.67% from the prior estimate of $105.23 dated September 29, 2026. These figures represent an aggregate of analyst targets compiled by Fintel and do n
- Fintel · Oct 22, 10:48 PM EDTDisc Medicine, Inc. Closes Public Offering of 6,000,000 Shares of Common StockOn October 20, 2026, Disc Medicine, Inc. entered into an Underwriting Agreement with Jefferies LLC, Leerink Partners LLC, Morgan Stanley & Co. LLC and Cantor Fitzgerald & Co., as representatives of the several underwriters, relating to an underwritten public offering of 6
- RTTNews · Oct 20, 10:08 PM EDTDisc Medicine Prices $450 Mln Offering Of Shares At $75/shr To Fund Pipeline Development(RTTNews) – Disc Medicine, Inc. (IRON), a clinical-stage biopharmaceutical company, announced the pricing of an upsized underwritten public offering of 6 million shares of common stock at a public offering price of $75.00 per share. The aggregate gross proceeds to Disc from this
- Barchart · Oct 20, 1:05 PM EDTStocks Settle Higher as Chipmakers and AI-Infrastructure Stocks ReboundThe S&P 500 Index ($SPX ) (SPY ) closed up by +0.41% on Monday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down by -0.07%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.17%. December E-mini S&P futures (ESZ26 ) rose +0.43%, and December E-mini…
- RTTNews · Oct 19, 11:49 PM EDTDisc Medicine Launches $350M Stock Offering Following Positive Phase 3 Results(RTTNews) – Disc Medicine, Inc. (IRON) announced a proposed underwritten public offering of $350 million of its common stock and, for certain investors, pre-funded warrants to purchase common stock.
- Barchart · Oct 19, 7:35 PM EDTStrength in Chipmakers and AI-Infrastructure Stocks Lead the Broader Market HigherThe S&P 500 Index ($SPX ) (SPY ) is up by +0.57% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down by -0.11%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.52%. December E-mini S&P futures (ESZ26 ) are up +0.58%, and December E-mini…
- Barchart · Oct 19, 7:13 PM EDTStocks Supported by a Rebound in Chipmakers and AI-Infrastructure CompaniesThe S&P 500 Index ($SPX ) (SPY ) is up by +0.51% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down by -0.17%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.20%. December E-mini S&P futures (ESZ26 ) are up +0.48%, and December E-mini…
- RTTNews · Oct 19, 3:42 PM EDTBiotech Stocks Rally: SLN Soars 125%, WORX Jumps 105%, IRON Gains 41%(RTTNews) – Biotech and healthcare stocks surged on Monday, drawing investor attention to Silence Therapeutics' $1.3 billion acquisition deal, SCWorx's new healthcare agreement and Disc Medicine's positive Phase 3 trial results. The developments highlighted acquisition-driven ups
- MarketBeat · Oct 19, 12:02 PM EDTDisc Medicine’s Bitopertin Nails Phase III Endpoints, Eyes FDA ResubmissionDisc Medicine (NASDAQ:IRON) said its Phase III APOLLO trial of investigational bitopertin met both co-primary endpoints and all secondary endpoints in patients with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), supporting the company’s plan to resubmit a
- RTTNews · Oct 19, 8:51 AM EDTDisc Medicine's Bitopertin Meets All Phase 3 Goals; FDA Resubmission Planned(RTTNews) – Disc Medicine, Inc. (IRON) reported positive topline results from the pivotal Phase 3 APOLLO trial of bitopertin in adults and adolescents with erythropoietic protoporphyria (EPP), with the investigational therapy meeting all primary and secondary endpoints.
- RTTNews · Oct 19, 5:59 AM EDTDisc Medicine Set To Report Phase 3 Bitopertin Results In Rare Blood Disorder; Stock Up(RTTNews) – Disc Medicine, Inc. (IRON) is scheduled to release topline results today from the Phase 3 APOLLO trial evaluating Bitopertin in patients with erythropoietic protoporphyria (EPP), a rare inherited blood disorder. The company will discuss the findings during a corporate
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Disc Medicine, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.